Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 18th Preview)
-
Gene therapy approval in ultra-rare neurodegeneration
The FDA approved Ultragenyx’s gene therapy Fayuvi (rebisufligene etisparvovec) for Sanfilippo syndrome type A (MPS IIIA), making it the first specifically approved treatment for the ultra-rare, fatal lysosomal storage disorder. The approval follows a prior 2025 complete response letter and is based on an open-label, single-arm pediatric study.
-
Reverse-merger funding for next-generation inflammation drugs
North Immunology is taking the reverse-merger route to reach the public markets, combining with Aethlon Medical in a deal that would provide about $180 million for its long-acting inflammation and immunology program. The company’s lead asset is designed for eczema, positioning its bispecific approach against existing immune disorder therapies.
-
Big IPO momentum in biotech
Electra Therapeutics priced a $350 million Nasdaq IPO, joining a wave of large 2026 listings and signaling continued appetite for commercial-stage biotech funding. The proceeds are slated to support Electra’s shift toward commercialization as investors evaluate its pipeline and platform progress in a crowded market.
-
FDA oversight focus: accelerate early U.S. trials and expand foreign site audits
The FDA launched two related moves aimed at shifting more early drug development into the U.S. and tightening inspection capacity abroad. First, it opened applications for an expedited investigational new drug (IND) pilot under Operation Trialblazer, offering rolling review support for up to 10 qualified institution–sponsor pairings. Separately, the agency plans to expand foreign bioresearch monitoring (BIMO) inspections and refine risk-based audit site selection.
-
Massive platform deal for bispecific antibody discovery
Roche signed up Dualitas Therapeutics to run a broad bispecific screening effort using Dualitas’ Dualscreen engine, with deal economics reaching up to $1 billion. Dualitas will screen more than 300,000 tethered bispecific combinations for synergistic immunology and inflammation effects compared with individual antibodies, receiving $36.5 million upfront and additional milestone payments plus royalties.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.